Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies

Stefan Runkel; Frank Kowalzik; Stephan Gehring; Julia Winter; Roman Kloeckner; Aline Mahringer-Kunz; Antonia Viertel; Caine L. Grandt; Manuela Marron; Susanne Seifert-Hitzler; Walter E. Hitzler

doi:10.7754/Clin.Lab.2021.210441

Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies

Stefan Runkel^*, Frank Kowalzik, Stephan Gehring, Julia Winter, Roman Kloeckner, Aline Mahringer-Kunz, Antonia Viertel, Caine L. Grandt, Manuela Marron, Susanne Seifert-Hitzler, Walter E. Hitzler

^*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Background: In the course of the current SARS-CoV-2 pandemic, antibody assays provide an important means for guidance of public health efforts. Thus, characterization of the course of antibody signals on different widely used assays is needed.

Methods: We selected 25 PCR-confirmed SARS-CoV-2 cases among 3,273 healthcare workers and measured the course of the antibody signal using the Abbott Architect SARS-CoV-2 IgG assay and the Roche Elecsys® Anti-SARS-CoV-2 immunoassay. The signal strength was then modelled using linear mixed models adjusted for age.

Results: Since first sampling, the assay signal decreased per day in the Abbott assay (standardized slope (β) = -0.46, 95% CI = -0.54 to -0.39). In contrast, an increase in the signal was ascertained by the Roche immunoassay per day (β = 0.25, 95% CI = 0.09 to 0.41).

Conclusions: Roche Elecsys® Anti-SARS-CoV-2 immunoassay may exhibit greater sensitivity in detecting SARS-CoV-2-specific antibodies in individuals in late stages of postinfection.

Originalsprache	Englisch
Zeitschrift	Clinical Laboratory
Jahrgang	67
Ausgabenummer	12
Seiten (von - bis)	2742-2747
Seitenumfang	6
ISSN	1433-6510
DOIs	https://doi.org/10.7754/Clin.Lab.2021.210441
Publikationsstatus	Veröffentlicht - 2021

Fördermittel

This study received no financial support from a specific funding agency.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 9 – Industrie, Innovation und Infrastruktur

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Biomedizintechnik
Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

DFG-Fachsystematik

2.22-30 Radiologie
2.21-05 Immunologie

Dokumente

10.7754/Clin.Lab.2021.210441

Weitere Links

Link to publication in Scopus

Zitieren

Runkel, S., Kowalzik, F., Gehring, S., Winter, J., Kloeckner, R., Mahringer-Kunz, A., Viertel, A., Grandt, C. L., Marron, M., Seifert-Hitzler, S., & Hitzler, W. E. (2021). Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies. Clinical Laboratory, 67(12), 2742-2747. https://doi.org/10.7754/Clin.Lab.2021.210441

@article{312a84d9a00f4018a4e692c2521e4a3a,

title = "Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies",

abstract = "Background: In the course of the current SARS-CoV-2 pandemic, antibody assays provide an important means for guidance of public health efforts. Thus, characterization of the course of antibody signals on different widely used assays is needed. Methods: We selected 25 PCR-confirmed SARS-CoV-2 cases among 3,273 healthcare workers and measured the course of the antibody signal using the Abbott Architect SARS-CoV-2 IgG assay and the Roche Elecsys{\textregistered} Anti-SARS-CoV-2 immunoassay. The signal strength was then modelled using linear mixed models adjusted for age. Results: Since first sampling, the assay signal decreased per day in the Abbott assay (standardized slope (β) = -0.46, 95\% CI = -0.54 to -0.39). In contrast, an increase in the signal was ascertained by the Roche immunoassay per day (β = 0.25, 95\% CI = 0.09 to 0.41). Conclusions: Roche Elecsys{\textregistered} Anti-SARS-CoV-2 immunoassay may exhibit greater sensitivity in detecting SARS-CoV-2-specific antibodies in individuals in late stages of postinfection.",

author = "Stefan Runkel and Frank Kowalzik and Stephan Gehring and Julia Winter and Roman Kloeckner and Aline Mahringer-Kunz and Antonia Viertel and Grandt, \{Caine L.\} and Manuela Marron and Susanne Seifert-Hitzler and Hitzler, \{Walter E.\}",

year = "2021",

doi = "10.7754/Clin.Lab.2021.210441",

language = "English",

volume = "67",

pages = "2742--2747",

journal = "Clinical Laboratory",

issn = "1433-6510",

publisher = "Verlag Klinisches Labor GmbH",

number = "12",

}

TY - JOUR

T1 - Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies

AU - Runkel, Stefan

AU - Kowalzik, Frank

AU - Gehring, Stephan

AU - Winter, Julia

AU - Kloeckner, Roman

AU - Mahringer-Kunz, Aline

AU - Viertel, Antonia

AU - Grandt, Caine L.

AU - Marron, Manuela

AU - Seifert-Hitzler, Susanne

AU - Hitzler, Walter E.

PY - 2021

Y1 - 2021

N2 - Background: In the course of the current SARS-CoV-2 pandemic, antibody assays provide an important means for guidance of public health efforts. Thus, characterization of the course of antibody signals on different widely used assays is needed. Methods: We selected 25 PCR-confirmed SARS-CoV-2 cases among 3,273 healthcare workers and measured the course of the antibody signal using the Abbott Architect SARS-CoV-2 IgG assay and the Roche Elecsys® Anti-SARS-CoV-2 immunoassay. The signal strength was then modelled using linear mixed models adjusted for age. Results: Since first sampling, the assay signal decreased per day in the Abbott assay (standardized slope (β) = -0.46, 95% CI = -0.54 to -0.39). In contrast, an increase in the signal was ascertained by the Roche immunoassay per day (β = 0.25, 95% CI = 0.09 to 0.41). Conclusions: Roche Elecsys® Anti-SARS-CoV-2 immunoassay may exhibit greater sensitivity in detecting SARS-CoV-2-specific antibodies in individuals in late stages of postinfection.

AB - Background: In the course of the current SARS-CoV-2 pandemic, antibody assays provide an important means for guidance of public health efforts. Thus, characterization of the course of antibody signals on different widely used assays is needed. Methods: We selected 25 PCR-confirmed SARS-CoV-2 cases among 3,273 healthcare workers and measured the course of the antibody signal using the Abbott Architect SARS-CoV-2 IgG assay and the Roche Elecsys® Anti-SARS-CoV-2 immunoassay. The signal strength was then modelled using linear mixed models adjusted for age. Results: Since first sampling, the assay signal decreased per day in the Abbott assay (standardized slope (β) = -0.46, 95% CI = -0.54 to -0.39). In contrast, an increase in the signal was ascertained by the Roche immunoassay per day (β = 0.25, 95% CI = 0.09 to 0.41). Conclusions: Roche Elecsys® Anti-SARS-CoV-2 immunoassay may exhibit greater sensitivity in detecting SARS-CoV-2-specific antibodies in individuals in late stages of postinfection.

UR - https://www.scopus.com/pages/publications/85122773272

U2 - 10.7754/Clin.Lab.2021.210441

DO - 10.7754/Clin.Lab.2021.210441

M3 - Journal articles

C2 - 34910439

AN - SCOPUS:85122773272

SN - 1433-6510

VL - 67

SP - 2742

EP - 2747

JO - Clinical Laboratory

JF - Clinical Laboratory

IS - 12

ER -

Longitudinal Study of the Signal Strength in two Serologic Assays for Detection of SARS-CoV-2 Specific Antibodies

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren